Why Choose Ipamorelin?
Ipamorelin is a synthetic pentapeptide that functions as a highly selective agonist of the ghrelin receptor (GHS-R1a) . It was originally developed in Denmark and entered a Phase II clinical trial for the treatment of intestinal pseudo-obstruction, though development was halted due to a lack of demonstrated efficacy . Unlike broader-acting growth hormone secretagogues, ipamorelin is designed to stimulate growth hormone release with minimal impact on other hormonal pathways such as prolactin and cortisol, making it a targeted tool for research into the GH axis .
The History & Origins
Ipamorelin was developed as a small peptide consisting of five amino acids, derived from growth hormone-releasing peptide 1 (GHRP-1) . It is a synthetic analogue designed to mimic ghrelin—the “hunger hormone” produced primarily in the stomach—by binding to and activating the growth hormone secretagogue receptor (GHS-R1a) . The peptide’s development was driven by a desire to create a more selective compound that could stimulate growth hormone release while avoiding the off-target effects associated with earlier, less specific secretagogues. Its distinct amino acid sequence and chirality are critical for its affinity and pharmacological action as a ghrelin receptor agonist .
How It Works: Distinct Mechanisms
Ipamorelin operates through a mechanism of action that distinguishes it from other peptide-based research tools, particularly by targeting ghrelin receptors in the hypothalamus and pituitary .
Ghrelin Receptor Agonist Mechanism
-
Selective GHS-R1a binding — Ipamorelin selectively binds to ghrelin receptors (GHS-R1a) located in the brain and peripheral organs including the gastrointestinal tract, heart, lung, liver, kidney, pancreas, and adipose tissue .
-
Growth hormone stimulation — The activation of GHS-R1a leads to the release of growth hormone from the anterior pituitary, which influences numerous anabolic processes .
-
Minimal off-target hormone effects — Ipamorelin is notable for its ability to stimulate growth hormone release without significantly affecting adrenocorticotropic hormone (ACTH) or cortisol levels, setting it apart from non-selective secretagogues .
Gastrointestinal Motility Research
-
Impact on gastric function — As a ghrelin mimetic, ipamorelin has been studied for its ability to stimulate gastric motility. Research in rodent models of postoperative ileus has shown that ipamorelin can accelerate colonic transit and increase fecal pellet output .
-
Mechanism of action — Ghrelin receptor activation in the stomach facilitates vagal control of gastric motility and stimulates gastric acid secretion .
Research Applications
-
Metabolic studies — Ipamorelin has been associated with the ability to stimulate food intake, body weight gain, and modulate fat processing and overall energy usage .
-
Postoperative ileus research — Studies have explored ipamorelin’s potential to accelerate recovery in models of intestinal dysfunction .
Quality & Specifications
Ipamorelin is a synthetic pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ . It is typically provided as a lyophilized powder, commonly in an acetate salt form, with purity specifications of ≥98% as verified by HPLC. Synonyms include NNC 26-0161 and the acetate salt form . Common peptide synthesis approaches produce ipamorelin as a trifluoroacetate (TFA) salt .
What’s the Difference Between Ipamorelin and Tesamorelin?
While both ipamorelin and tesamorelin are growth hormone-related peptides, they operate through entirely distinct biological pathways and have different research profiles .
Ipamorelin acts as a ghrelin receptor (GHS-R1a) agonist. It mimics ghrelin and triggers a rapid, pulsatile release of growth hormone with a high degree of receptor selectivity, minimizing effects on prolactin and cortisol . It is currently considered a research compound with limited clinical trial data and no FDA approval for any human indication .
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), a 44-amino-acid peptide that stimulates the pituitary somatotroph cells to synthesize and release endogenous growth hormone . Unlike ipamorelin, tesamorelin works through a different receptor (GHRH receptor) and has a more sustained, cumulative effect . Tesamorelin is approved by the FDA for the treatment of HIV-associated lipodystrophy to reduce excess abdominal fat, supported by a robust body of clinical trial evidence
